35 related articles for article (PubMed ID: 11039669)
1. Overexpression of lung resistance-related protein and P-glycoprotein and response to induction chemotherapy in acute myelogenous leukemia.
Tsuji K; Wang YH; Takanashi M; Odajima T; Lee GA; Sugimori H; Motoji T
Hematol Rep; 2012 Jul; 4(3):e18. PubMed ID: 23087807
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
Morita Y; Kanamaru A; Miyazaki Y; Imanishi D; Yagasaki F; Tanimoto M; Kuriyama K; Kobayashi T; Imoto S; Ohnishi K; Naoe T; Ohno R
Int J Hematol; 2010 Jan; 91(1):97-103. PubMed ID: 20047095
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the international prognostic scoring system for determining chemotherapeutic indications in myelodysplastic syndrome: Japanese retrospective multicenter study.
Ito Y; Ohyashiki K; Hirai H; Ogawa S; Mitani K; Hotta T; Bessho M; Naoe T; Mizoguchi H; Uchiyama T; Omine M
Int J Hematol; 2005 Oct; 82(3):236-42. PubMed ID: 16207597
[TBL] [Abstract][Full Text] [Related]
4. Localized relapse in bone marrow in a posttransplantation patient with t(6;9) acute myeloid leukemia.
Maeda T; Kosugi S; Ujiie H; Osumi K; Fukui T; Yoshida H; Kashiwagi H; Ishikawa J; Tomiyama Y; Matsuzawa Y
Int J Hematol; 2003 Jun; 77(5):522-5. PubMed ID: 12841393
[TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
9. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
Okamoto T; Kanamaru A; Shimazaki C; Motoji T; Takemoto Y; Takahashi M; Fukushima T; Takeshita A; Kusumoto GS; Kishimoto Y; Yorimitsu S; Tsukuda K; Uike N; Arima N; Ohno R
Int J Hematol; 2000 Aug; 72(2):200-5. PubMed ID: 11039669
[TBL] [Abstract][Full Text] [Related]
11. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
12. [Intensive chemotherapy in myelodysplastic syndromes].
Dombret H
Pathol Biol (Paris); 1997 Oct; 45(8):627-35. PubMed ID: 9569928
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
